July 6, 2020 -- Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention of COVID-19.
The phase III prevention trial will investigate REGN-COV2's ability to prevent infection among uninfected high-risk individuals and is being jointly run by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The antibody cocktail has also moved into parts two and three of the adaptive phase I/II/III trials, testing its ability to treat COVID-19 patients.
The phase III prevention trial is being conducted at nearly 100 sites and is expected to enroll 2,000 patients in the U.S. The phase II/III treatment trials are planned for 150 sites in the U.S., Brazil, Mexico, and Chile to evaluate virology and clinical endpoints, with preliminary data expected later this summer.
REGN-COV2 contains two potent, noncompeting, neutralizing antibodies using Regeneron's in-house VelociMab platform and manufacturing capabilities.